A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Public ClinicalTrials.gov record NCT02006472. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45, 67.5, 90, and 112.5 mg Twice-Daily vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's Disease (HD).
Study identification
- NCT ID
- NCT02006472
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 408 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2014 (Actual)
- Primary completion
- Dec 16, 2015 (Actual)
- Completion
- Jul 7, 2016 (Actual)
- Last update posted
- Jul 19, 2021
2014 – 2016
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site 12199 | La Jolla | California | — | — |
| Investigational Site 12204 | Los Angeles | California | — | — |
| Investigational Site 12201 | Englewood | Colorado | — | — |
| Investigational Site 12196 | Washington D.C. | District of Columbia | — | — |
| Investigational Site 12207 | Chicago | Illinois | — | — |
| Investigational Site 12202 | Baltimore | Maryland | — | — |
| Investigational Site 12206 | Baltimore | Maryland | — | — |
| Investigational Site 12200 | Manhasset | New York | — | — |
| Investigational Site 12203 | New York | New York | — | — |
| Investigational Site 12198 | Rochester | New York | — | — |
| Investigational Site 12211 | Winston-Salem | North Carolina | — | — |
| Investigational Site 12205 | Cincinnati | Ohio | — | — |
| Investigational Site 12209 | Pittsburgh | Pennsylvania | — | — |
| Investigational Site 12208 | Salt Lake City | Utah | — | — |
| Investigational Site 12210 | Richmond | Virginia | — | — |
| Investigational Site 12197 | Kirkland | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02006472, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2021 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02006472 live on ClinicalTrials.gov.